Second chance: drug combo retested for tough colorectal cancer
NCT ID NCT07178717
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether giving the drugs encorafenib and cetuximab again can help people with a specific type of advanced colorectal cancer (BRAF V600E-mutant) whose disease got worse after prior treatment with similar drugs. About 25 participants will receive the drug combination until their cancer progresses or side effects become too severe. The main goal is to see how many patients are alive without their cancer getting worse after 4 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
encorafenib and cetuximab
What this could lead to
If successful, this could provide a new treatment option for patients with a specific type of advanced colorectal cancer whose disease has progressed after initial BRAF inhibitor therapy.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The treatment may not control the cancer for long, and side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
Contact Email: •••••@•••••